Methods of treating ulcerative colitis
Methods for maintaining clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human alpha4beta7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-alpha4beta7 antibody in vivo.
1. A method for treating a human patient suffering from moderately to severely active ulcerative colitis, wherein the method comprises the steps of:
administering to a human patient suffering from moderately to severely active ulcerative colitis, an initial 300 mg dose of a humanized antibody having binding specificity for human alpha4beta7 integrin;
administering a second subsequent dose of 300 mg of the humanized antibody two weeks after the initial dose;
administering a third subsequent dose of 300 mg of the humanized antibody six weeks after the initial dose; and
administering subsequent doses of 300 mg of the humanized antibody every eight weeks after the third subsequent dose of the humanized antibody;
wherein the humanized antibody is an IgG1 isotype, comprises a light chain comprising CDRs as set forth in SEQ ID NO: 11 (CDR1), SEQ ID NO: 12 (CDR2), and SEQ ID NO: 13 (CDR3), and comprises a heavy chain comprising CDRs as set forth in SEQ ID NO: 8 (CDR1), SEQ ID NO: 9 (CDR2), and SEQ ID NO: 10 (CDR3),
wherein the human patient had an inadequate response or intolerance to azathioprine or 6-mercaptopurine over a previous 5 year period, and
wherein clinical response of moderately to severely active ulcerative colitis is achieved at 6 weeks after the initial dose, and clinical remission of moderately to severely active ulcerative colitis is achieved at 52 weeks after the initial dose in the human patient.
2. A method for treating a human patient suffering from moderately to severely active ulcerative colitis, wherein the method comprises the steps of:
administering to a patient suffering from moderately to severely active ulcerative colitis, an initial 300 mg dose of vedolizumab;
administering a second subsequent dose of 300 mg of vedolizumab two weeks after the initial dose;
administering a third subsequent dose of 300 mg of vedolizumab six weeks after the initial dose; and
administering subsequent doses of 300 mg of vedolizumab every eight weeks after the third subsequent dose,
wherein the human patient had an inadequate response or intolerance to azathioprine or 6-mercaptopurine over a previous 5 year period, and
wherein clinical response of moderately to severely active ulcerative colitis is achieved at 6 weeks after the initial dose, and clinical remission of moderately to severely active ulcerative colitis is achieved at 52 weeks after the initial dose in the human patient.
3. The method of claim 1 , wherein the light chain comprises a variable region comprising amino acids 20 to 131 of SEQ ID NO: 4, or amino acids 21 to 132 of SEQ ID NO: 5, and the heavy chain comprises a variable region comprising amino acids 20 to 140 of SEQ ID NO: 2.
4. The method of claim 1 , wherein the light chain comprises a variable region that is 95% identical to amino acids 20 to 131 of SEQ ID NO: 4, or amino acids 21 to 132 of SEQ ID NO: 5, and the heavy chain comprises a variable region that is 95% identical to amino acids 20 to 140 of SEQ ID NO: 2.
5. The method of claim 1 , wherein the humanized antibody is administered every four weeks if the human patient experiences a return of one or more disease symptoms following administration of the humanized antibody every eight weeks.
6. The method of claim 2 , wherein vedolizumab is administered every four weeks if the human patient experiences a return of one or more disease symptoms following administration of vedolizumab every eight weeks.
7. The method of claim 1 , wherein the human patient is 65 years or older.
8. The method of claim 2 , wherein the human patient is 65 years or older.
9. The method of claim 1 , wherein the dose of the humanized antibody is administered intravenously.
10. The method of claim 2 , wherein the dose of vedolizumab is administered intravenously.
11. The method of claim 9 , wherein the dose is administered to the human patient in about 30 minutes.
12. The method of claim 10 , wherein the dose is administered to the human patient in about 30 minutes.